RHOEN-KLINIKUM (ETR:RHK) target price raised to 31.00EUR, reported today by Commerzbank AG
- Updated: October 7, 2016
Yesterday RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even at 26.52EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last stock close price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 0
RHOEN-KLINIKUM (ETR:RHK) had its target price raised to 31.00EUR by Commerzbank AG in a report released 10/07/2016. The new target price indicates a possible upside of 0.17% based on the company's last stock close price.
Previously on Thursday September 22, 2016, Joh. Berenberg Gossler & Co. KG reported about RHOEN-KLINIKUM (ETR:RHK) raised the target price from 0.00EUR to 28.00EUR. At the time, this indicated a possible upside of 0.03%.
See Chart Below
RHOEN-KLINIKUM has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR The company’s market cap is currently 0 EUR.
General Information About RHOEN-KLINIKUM (ETR:RHK)
Rhoen Klinikum AG is a Germany-based provider of health care services. It operates acute hospitals, medical care centers and rehabilitation hospitals across Germany: six clinics on Campus Bad Neustadt, including the Cardiovascular Clinic, the Frankenklinik for the Rehabilitation of Cardiovascular Patients, the Clinic for Hand Surgery, the Neurological Clinic, the Psychosomatic Clinic and the Saaletalklinik with two additional addiction therapy facilities; Klinikum Frankfurt (Oder) comprises clinics, psychiatric outpatient institutions and day clinics; University Hospital Giessen and Marburg (UKGM) offers medical services, modern diagnostics and comprehensive therapy in various areas, including ophthalmology, trauma surgery and dentistry, and Zentralklinik Bad Berka provides health care services to patients with thoracic, pulmonary and vascular diseases, tumors, neurological conditions, and diseases of the spinal column, joints and heart, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.